Catalyst

Slingshot members are tracking this event:

First Patient Enrolled in Bayer (BAYRY) and Merck's (MRK) Phase 3 VICTORIA Trial Assessing Vericiguat in Chronic Heart Failure Without Reduced Ejection Fraction

Source Link:
http://www.news.bayer.com/baynews/baynews.nsf/id/Pivotal-Phase-III-Study-Started-With-Vericiguat-in-Patients-With-Chronic-Heart-Failure?OpenDocument&sessionID=1475055797

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MRK
100%
BAYRY
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 28, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Victoria Trial, Vericiguat, Chronic Heart Failure, Reduced Ejection Fraction
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.